DRI Healthcare Comments on Juvmo’s (tavapadon) FDA Approval
TORONTO, Sept. 28, 2026 /CNW/ — DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare“) today commented on the U.S. Food and Drug Administration’s (“FDA”) recently announced approval of Juvmo (tavapadon) for the treatment of motor symptoms that occur in Parkinson’s disease. Juvmo (tavapadon) is a novel selective dopamine D1/D5 receptor partial agonist developed as a once-daily oral treatment […]
DRI Healthcare Announces US$316 Million Purchase of Tavapadon Royalty
– DRI Healthcare to acquire royalty participation rights on tavapadon for an aggregate purchase price of US$316 million upon FDA approval of tavapadon –– Tavapadon is a novel oral dopamine-D1R/D5R partial agonist that has been submitted to the FDA for approval for the treatment of Parkinson’s disease –– DRI Healthcare to host investor call on Monday, September […]
DRI Healthcare Announces Receipt of Put Price on EKTERLY
TORONTO, Aug. 11, 2026 /CNW/ — DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare“) today announced that it has received the Put Price of approximately US$178 million in connection with its previously announced exercise of the contractual put option with respect to its royalty participation right in EKTERLY (the “Put Option“). As previously announced on July […]
DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment
TORONTO, Aug. 7, 2026 /CNW/ — DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”) today announced its financial results for the quarter ended June 30, 2026. DRI Healthcare’s second quarter 2026 financial statements and Management’s Discussion & Analysis (“MD&A”) have been filed on SEDAR+ (www.sedarplus.ca). All dollar amounts are expressed in U.S. dollars unless otherwise indicated. “We are pleased […]
DRI Healthcare to Host Second Quarter 2026 Earnings Call and Webcast on August 10, 2026
TORONTO, July 20, 2026 /CNW/ — DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”), a global leader in providing financing to advance innovation in the life sciences industry, announces that it will hold a conference call to discuss its second quarter 2026 financial results on Monday, August 10, 2026, at 8:00 a.m. ET. DRI Healthcare […]
DRI Healthcare Announces Exercise of Put Option on EKTERLY®
TORONTO, July 10, 2026 /CNW/ — DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare“) today announced that it has exercised its contractual put option (the “Put Option“) with respect to DRI Healthcare’s royalty participation right in EKTERLY® (sebetralstat) for a total net repurchase price of approximately US$178 million (“Put Price“). The Put Option has been exercised in […]
DRI Healthcare Comments on Viridian’s FDA Approval and Launch of Lumvoa™ (veligrotug-vvze)
TORONTO, June 29, 2026 /CNW/ DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare“) today commented on Viridian Therapeutics, Inc.’s (“Viridian“) recently announced approval by the U.S. Food and Drug Administration (“FDA”) of Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (“TED“). TED is an autoimmune inflammatory disorder of the orbit (eye socket) that affects numerous […]
DRI Healthcare Trust Announces Voting Results of Annual and Special Meeting
TORONTO, May 15, 2026 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”) is pleased to announce results of voting at its annual and special meeting of unitholders held on May 15, 2026. All of the nominees for election as trustees of DRI Healthcare referred to in its management information circular dated April 13, 2026 were elected […]
DRI Healthcare Reports First Quarter 2026 Results
TORONTO, March 14, 2026 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”) today announced its financial results for the quarter ended March 31, 2026. DRI Healthcare’s first quarter 2026 financial statements and Management’s Discussion & Analysis (“MD&A”) have been filed on SEDAR+ (www.sedarplus.ca). All dollar amounts are expressed in U.S. dollars unless otherwise indicated. “We began this […]
DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc.
TORONTO, April 29, 2026 /CNW/ DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare“) today noted the announcement by KalVista Therapeutics, Inc. (“KalVista”), that it has entered into a definitive agreement to be acquired by Chiesi Group, an international research-focused biopharmaceutical group (the “Transaction”). DRI Healthcare congratulates KalVista on the announced Transaction. As previously disclosed, DRI Healthcare […]